Legend Biotech (NASDAQ: LEGN) director discloses shares, RSUs and options

Rhea-AI Filing Summary

Legend Biotech Corp director Casey Patrick John filed an initial ownership report showing existing equity holdings. The filing lists 54,604 Ordinary Shares held directly, including 25,674 restricted share units that vest in scheduled quarterly installments starting on March 20, 2026 and June 20, 2026. It also reports a Share Option for 30,000 Ordinary Shares at an exercise price of 14.1200 per share, expiring on March 28, 2031, which is immediately exercisable. The company notes each ADS represents two Ordinary Shares.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Casey Patrick John

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)	54,604(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	(3)	03/28/2031	Ordinary Shares	30,000	$14.12	D

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. Includes 25,674 restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 7,136 RSUs have settled, with the remainder vesting (i) as to 2,100 RSUs, in 3 equal quarterly installments beginning on March 20, 2026, (ii) as to 5,888 RSUs, in equal 7 quarterly installments beginning on March 20, 2026, and (iii) as to 10,550 RSUs, with 25% of the shares vesting on June 20, 2026 with the remainder vesting in 8 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

3. All of the shares subject to the option are immediately exercisable.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ James Pepin, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Casey Patrick John report owning in Legend Biotech (LEGN) on this Form 3?

The Form 3 reports existing holdings, not a new trade. Casey Patrick John holds 54,604 Ordinary Shares directly, plus a Share Option over 30,000 Ordinary Shares at an exercise price of 14.1200 per share, expiring on March 28, 2031.

How many RSUs does Casey Patrick John hold in Legend Biotech (LEGN)?

The filing shows 25,674 restricted share units (RSUs). Each RSU represents a contingent right to receive one Ordinary Share upon settlement. Of these, 7,136 RSUs have already settled, with the remaining RSUs vesting over multiple future quarterly installments.

What are the vesting terms of the Legend Biotech (LEGN) RSUs reported on this Form 3?

The remaining RSUs vest in several quarterly schedules. 2,100 RSUs vest in 3 equal quarterly installments from March 20, 2026, 5,888 vest in 7 equal quarterly installments from that date, and 10,550 vest 25% on June 20, 2026 with the rest over 8 quarterly installments.

What are the key terms of the share option reported by Casey Patrick John in Legend Biotech (LEGN)?

The share option covers 30,000 Ordinary Shares. It has an exercise price of 14.1200 per share, is immediately exercisable, and expires on March 28, 2031. This option position is held directly, according to the disclosure.

How are Legend Biotech (LEGN) Ordinary Shares represented by ADSs in this Form 3?

The filing clarifies the ADS-to-share conversion. Legend Biotech states its Ordinary Shares may be represented by American Depositary Shares (ADSs), and that each ADS represents two Ordinary Shares of the issuer, linking U.S.-traded ADSs to underlying equity.

Does this Legend Biotech (LEGN) Form 3 indicate any recent share purchases or sales?

No purchases or sales are identified in this Form 3. The entries are classified as holdings, with unknown transaction codes, and the transaction summary shows no buy, sell, exercise, gift, or tax-withholding events, only disclosure of existing positions.